Case Report

Unexplained dyspnea in a patient of chronic arsenicosis: A diagnostic challenge and learning curve for physicians Amitabha Sengupta, Arnab Maji, Debraj Jash, Malay Maikap Department of Pulmonary Medicine, Nil Ratan Sarkar Medical College, Kolkata, West Bengal, India

ABSTRACT Chronic arsenic exposure causes cutaneous effects like hyperkeratosis, peripheral vascular disease, hypertension, ischemic heart disease, non‑cirrhotic portal hypertension, hepatomegaly, peripheral neuropathy, respiratory involvement, bad obstetrical outcome, hematological disturbances, and diabetes mellitus. Here we present a case of a 24‑year‑old lady, with chronic exposure to arsenic, presenting to us with progressive dyspnea. We found pulmonary arterial hypertension (PAH) as a cause of her dyspnea. PAH can occur in arsenicosis, secondary to arsenic‑induced chronic obstructive pulmonary disease  (COPD), lung fibrosis, and portal hypertension, which we excluded by appropriate investigations in our case. We also excluded a familial or heritable form of PAH. Thus, with the exclusion of all these secondary causes of PAH, as well as a hereditary cause, we came to a conclusion that this PAH might be due to chronic arsenic exposure. To the best of our knowledge, no case of PAH in chronic arsenicosis has been reported to date.

KEY WORDS: Chronic arsenicosis, dyspnea, pulmonary arterial hypertension Address for correspondence: Dr. Arnab Maji, 2 No Ichlabad, Barabenepara, P.O. – Sripally, Burdwan – 713103, West Bengal, India E‑mail: [email protected]



Arsenic is an element that has raised concern from both the environmental and human health standpoints since the dawn of civilization. Chronic exposure, most commonly, is due to prolonged ingestion of water containing elevated levels of arsenic.[1] A report in 2001, has stated that around 150 million people are at risk from arsenic‑contaminated ground water in the combined areas of West Bengal and its neighboring country, Bangladesh. [2] Dyspnea may occur in chronic arsenicosis due to heart failure, because of atherosclerotic hypertensive heart diseases, arsenic‑induced restrictive pulmonary diseases, and portopulmonary hypertension.[3] In this case, we found isolated pulmonary arterial hypertension as the cause of dyspnea in a patient with chronic arsenicosis.

A 24‑year‑old, married girl, from the Nadia district of West Bengal, India, presented to us with progressive dyspnea for the last six months. She presented to us with dyspnea of Grade 4, as per the Modified Medical Research Council (MMRC) grading of dyspnea. She had cyanosis, resting oxygen saturation (SpO2) 81%, a pulse rate of 102/minute, blood pressure of 100/60 mmHg, and a respiratory rate of 26/minute. The internal jugular veins were engorged and pulsatile. Bilateral pitting pedal edema was present. On examination of her palm, hyperkeratosis and raindrop pigmentation was seen [Figure 1]. Examination of the respiratory system revealed no abnormality. On examination of her cardiovascular system, we found tachycardia and a loud pulmonary component of the second heart sound. Examination of her abdomen revealed a palpable tender liver. Thus, a clinical diagnosis of right heart failure was established. She was given oxygen at the rate of 6 liters/minute through a face mask. Her blood samples were sent for routine investigations. Her electrocardiogram revealed the presence of p‑pulmonale. The routine blood investigation showed hemoglobin 9.1 g/dl, total leukocyte count 11,400/cubic millimeter, with neutrophil 80%, lymphocytes 17%, eosinophils 2%, and monocytes 1%; urea

Access this article online Quick Response Code:

Website: DOI: 10.4103/0970-2113.152640

Lung India • Vol 32 • Issue 2 • Mar - Apr 2015 169

Sengupta, et al.: Dyspnea in chronic arsenicosis

23 mg/dl and creatinine 0.8 mg/dl; and sodium 133 mEq/L, potassium 3.7 mEq/L, and calcium 9.3 mg/dl. The liver function tests revealed no abnormality. Her enzyme‑linked immunosorbent assay (ELISA) for human immunodeficiency virus (HIV) 1 and 2 antigen testing was negative. Her chest x‑ray revealed no abnormality. Ultrasonography of the whole abdomen showed presence of mild hepatomegaly. Echocardiography revealed a grossly enlarged right ventricle and dilated right atrium, with intact an interatrial septum and interventricular septum and Grade 3 tricuspid regurgitation, with a measured mean pulmonary artery systolic pressure of 65 mmHg, which established the diagnosis of pulmonary arterial hypertension. We could not perform right heart catheterization due to lack of infrastructure. Transesophageal echocardiography (TEE) was also performed, but failed to reveal any intracardiac shunt [Figure 2]. Doppler‑ultrasonography (Doppler‑USG) of the abdomen revealed no evidence of portal hypertension. We sent her hair, nail, and drinking water from her residence to the School of Tropical Medicine in Kolkata for arsenic estimation and the report revealed 0.12 mg/L arsenic in the water sample (safe limit of arsenic content in drinking water is 0.05 mg/L in India and 0.01 mg/L, as per the World Health Organization statement), 2.66 µg/g in her hair, and 6.10 µg/g in her nail. High‑resolution computed tomography (HRCT) scan of her thorax did not reveal any parenchymal abnormality. On computed tomography (CT)‑angiography we found no embolus in the the pulmonary vasculature, but an enlarged main pulmonary artery trunk [Figure 3]. Subsequently, we planned to have investigations for connective tissue disorders (CTD), in order to detect the etiology of the pulmonary arterial hypertension (PAH). However, all our workups, including anti‑centromere antibody, anti‑ds DNA antibody, anti‑Ro, anti‑U3 and U1 RNP, and anti‑phospholipid antibody were negative. After all these investigations we were in fact left with the idiopathic or heritable form of PAH. We then took her family history in detail, but failed to illicit any history suggestive of PAH in her family, even after repeated enquiry. Serum analysis for bone morphogenetic protein receptor 2 (BMPR‑2) gene and activin receptor kinase‑like 1 (ALK‑1) gene failed to detect any mutation. We had virtually excluded almost all causes of PAH including familial causes. Thus, with the exclusion of all possible causes of PAH in the present case, we concluded that chronic arsenicosis may be responsible for PAH in this case.

Figure 1: Hyperkeratosis and raindrop pigmentation of the palm

Figure 2: Transesophageal echocardiography showing an enlarged right atrium and a right ventricle with intact interatrial septum and interventricular septum

DISCUSSION Arsenicosis is a multi‑system disorder, with virtually no system exempted from its involvement. Cutaneous effects take the form of pigmentary changes, hyperkeratosis, and skin cancers. Peripheral vascular disease, hypertension, ischemic heart disease, non‑cirrhotic portal hypertension, hepatomegaly, peripheral neuropathy, respiratory involvement, bad obstetrical outcome, hematological disturbances, and diabetes mellitus are among the other 170

Figure 3: CT angiography showing an enlarged main pulmonary artery

Lung India • Vol 32 • Issue 2 • Mar - Apr 2015

Sengupta, et al.: Dyspnea in chronic arsenicosis

clinical features linked to arsenic toxicity. The proposed mechanism of arsenic‑induced hypertension is accelerated atherosclerosis due to monoclonal expansion of smooth, production of reactive oxygen species, upregulation of inflammatory signals, and platelet aggregation.[4‑6] Respiratory manifestations of arsenicosis include chronic obstructive pulmonary disease (COPD), bronchiectasis, and pulmonary fibrosis. Pulmonary arterial hypertension, as per literature, can occur in arsenicosis, secondary to COPD, lung fibrosis, and portal hypertension. Pulmonary hypertension has been defined as an increase in mean pulmonary arterial pressure (PAP), ≥25 mmHg at rest, as assessed by right heart catheterization (RHC).[7] However, in our hospital there is no facility for RHC. We measured pulmonary artery systolic pressure by applying the formula (PA systolic pressure = tricuspid regurgitation pressure gradient + estimated right atrial pressure). Theoretically, the calculation of mean PAP from PA systolic pressure is possible (mean PAP = 0.61 × PA systolic pressure + 2 mmHg). Thus, we established the diagnosis of PAH in our patient. We excluded CTD by clinical examination and auto‑antibody profile, left heart diseases by echocardiography, intra‑cardiac shunt by TEE, portal hypertension by Doppler USG, pulmonary embolism by CT‑angiography, as the probable causes of PAH. In our workups we got no evidence of portal hypertension, COPD or interstitial lung diseases causing PAH. We also excluded the possibility of heritable and familial PAH. In literature, we did not find any case of arsenic‑induced isolated PAH. However, literature revealed many mechanisms causing endothelial dysfunction of systemic arteries like reactive oxygen species generation and inflammatory cascades mediated by cytokines in chronic arsenicosis patients.[6]

On the basis of the above‑mentioned mechanisms, we proposed that PAH in the present case might be due to chronic arsenic exposure and its toxicity. Careful attention to such cases in the future would provide more evidence of an association between the two conditions.


2. 3. 4.

5. 6. 7.

International Agency for Research on Cancer (WHO). Some Drinking‑water Disinfectants and Contaminants, Including Arsenic. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 84. Lyon, France: International Agency for Research on Cancer; 2004. p. 68‑73. Chakraborti D, Rahman MM, Paul K, Chowdhury UK, Sengupta MK, Lodh D, et al. Arsenic calamity in the Indian subcontinent what lessons have been learned? Talanta 2002;58:3‑22. Sengupta SR, Das NK, Datta PK. Pathogenesis, clinical features and pathology of chronic arsenicosis. Indian J Dermatol Venereol Leprol 2008;74:559‑70. Barchowsky A, Klei LR, Dudek EJ, Swartz HM, James PE. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic Biol Med 1999;27:1405‑12. Yu HS, Liao WT, Chang KL, Yu CL, Chen GS. Arsenic induces tumor necrosis factor alpha release and tumor necrosis factor receptor 1 signaling in T helper cell apoptosis. J Invest Dermatol 2002;119:812‑9. Kumar SV, Bhattacharya S. In vitro toxicity of mercury, cadmium, and arsenic to platelet aggregation: Influence of adenylate cyclase and phosphoesterase activity. In Vitr Mol Toxicol 2000;13:137‑44. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792‑800.

How to cite this article: Sengupta A, Maji A, Jash D, Maikap M. Unexplained dyspnea in a patient of chronic arsenicosis: A diagnostic challenge and learning curve for physicians. Lung India 2015;32:169-71. Source of Support: Nil, Conflict of Interest: None declared.

Attentions for Authors: If you wish to have the images printing in color, you needs to pay Rs. 4000/- (Rs. Four Thousand only). Otherwise those will be printed in black and white.

Lung India • Vol 32 • Issue 2 • Mar - Apr 2015 171

Copyright of Lung India is the property of Medknow Publications & Media Pvt. Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.

Unexplained dyspnea in a patient of chronic arsenicosis: A diagnostic challenge and learning curve for physicians.

Chronic arsenic exposure causes cutaneous effects like hyperkeratosis, peripheral vascular disease, hypertension, ischemic heart disease, non-cirrhoti...
870KB Sizes 2 Downloads 20 Views